Suzhou Basecare Medical Corporation Limited (HKG:2170)

Market Cap	533.38M -29.1%
Revenue (ttm)	302.12M +11.5%
Net Income	-261.45M
EPS	-0.96
Shares Out	273.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,500
Average Volume	155,225
Open	1.950
Previous Close	1.950
Day's Range	1.880 - 1.950
52-Week Range	1.810 - 4.450
Beta	0.23
RSI	43.98
Earnings Date	Mar 27, 2026

About HKG:2170

Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Republic of China and Australia. The company offers pre-implantation genetic test kits, including PGT-A kit to detect aneuploidy; PGT-M kit to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kit to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides DA500, a high-throughput gene sequencer that provi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 419
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2170

Financial Performance

In 2024, HKG:2170's revenue was 299.11 million, an increase of 43.82% compared to the previous year's 207.98 million. Losses were -237.03 million, 23.7% more than in 2023.

Financial numbers in CNY